<DOC>
	<DOCNO>NCT02653443</DOCNO>
	<brief_summary>The objective study test hypothesis INTERCEPT Blood System platelet component store 6 7 day INTERCEPT Blood System treatment retain sufficient viability therapeutic efficacy . The post-infusion recovery lifespan autologous INTERCEPT Blood System platelet component 35 % plasma/65 % InterSol ( Test platelet ) store 6 7 day measure comparison `` fresh '' autologous radiolabeled platelet ( Control platelets ) accord FDA guidance platelet test ( FDA 1999 ) . Recovery lifespan result component store 6 7 day also assess .</brief_summary>
	<brief_title>A Randomized , Multi-center , Open-label , Paired Controlled , Crossover In Vivo Study</brief_title>
	<detailed_description>For 2 study donation period , study follow procedure : single double dose platelet apheresis collection , pathogen inactivation INTERCEPT Blood System treatment , storage 6 7 day ( depend period randomization scheme ) 20°C 24°C agitation , collection `` fresh '' autologous platelet , radiolabeling , infusion fresh store INTERCEPT Blood System-treated radiolabeled autologous platelet , collection blood sample assessment platelet recovery survival ( lifespan ) . There minimum wash-out period two week two study period . Apheresis platelet collect use Amicus separator store 6 7 day ( depend period randomization scheme ) 35 % plasma/65 % InterSol . Procedures follow : On Day 0 , healthy volunteer subject apheresis platelet collect . INTERCEPT Blood System treatment begin either day donation ( Day 0 ) day follow donation ( Day 1 ) complete within 24 hour collection . Platelets store 6 7 day collection ( depend period randomization scheme ) 22°C ±2°C agitation . Aliquots vitro platelet function take Day 0/1 INTERCEPT Blood System treatment Day 6 7 . On Day 6 7 , healthy volunteer return site , 43 mL blood drawn syringe contain 9 mL Anticoagulant Citrate Dextrose Solution , Formula A ( ACD-A ) . Fresh platelet prepared sample . An aliquot ( 10-20 mL ) store INTERCEPT Blood System platelets aseptically remove subject 's test container . Previously store ( Test ) fresh ( Control ) platelet radiolabeled accord randomization assignment either Chromium-51 ( 51Cr ) ( ≤20 μCi ) sodium radiochromate ( Na251CrO4 ) Indium-111 ( 111In ) ( ≤15 μCi ) indium oxine , follow label wash procedure outline Biomedical Excellence Safer Transfusion ( BEST ) Collaborative . The isotope label assign randomly equal probability fresh platelet store INTERCEPT Blood System platelets label isotope. , randomization assignment isotope label utilized donation period subject . Aliquots fresh store platelet radiolabeled tubes standard technique . After radiolabeling , autologous fresh store INTERCEPT Blood System platelets simultaneously infuse subject ( approximately 10-30 mL ) . Negative pregnancy test female childbearing potential require infusion . Blood sample radioactivity measurement draw immediately infusion approximately 0 , 0.5 , 1 , 2 hour post-infusion , 6 sample draw 1 , 2 , 3 , 4 ( 6 ) , 7 , 11±1 day post-infusion , approximately time day radiolabeled platelet infusion administer ( ±4 hour ) . Patients monitor safety ( adverse event ) begin study 10 day follow infusion radiolabelled platelet period 2 . Radioactivity measurement Samples obtain radiolabeled fresh store INTERCEPT Blood System platelets infusion use radioactive standard . By measure volume infuse , total dose radioactivity infuse calculate . In vitro elution label transfuse platelet determine BEST elution assessment method , well vivo elution radioactivity serial blood sample obtain post-infusion labeled platelet . The standard well subject 's whole-blood sample correct elution also residual activity cellular fraction one day infusion . Data point 24 hour post-infusion use calculate vivo recovery radioactive correction make . The radioactivity sample determine use gamma counter . A multiple-hit model use estimate survival radioactively label platelet .</detailed_description>
	<criteria>Normal health status ( determine Investigator review medical history blood donor physical exam ) Meet FDA , American Association Blood Banks ( AABB ) , site guideline blood donation apheresis platelet donation Complete blood count ( CBC ) serum chemistry value within establish reference range within guideline . Predonation platelet count 150×10^9 platelets/L Negative blood donor screen test panel Human Immunodeficiency virus ( HIV ) , Hepatitis B virus ( HBV ) , Hepatitis C virus ( HCV ) , Human TLymphotropic virus ( HTLV ) , syphilis , West Nile virus ( WNV ) Male female subject childbearing potential must agree use medically acceptable method contraception throughout study . A barrier method contraception must include , regardless method . Signed date informed consent form Clinically significant acute chronic disease ( determined Investigator ) Pregnant nursing female Male female subject childbearing potential use effective contraception Disease state condition preclude blood donation apheresis platelet donation per AABB reference standard Treatment aspirin aspirincontaining medication within 7 day apheresis treatment nonsteroidal anti inflammatory drug ( NSAID ) , antiplatelet agent drug affect platelet viability within 3 day apheresis ( e.g . ibuprofen NSAIDs ) Subject receive platelet inhibitor within 14 day donation ( e.g . clopidogrel , ticlopidine ) Splenectomized subject History know hypersensitivity indium chromium Participation another clinical study currently within past 28 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>INTERCEPT</keyword>
	<keyword>Platelet</keyword>
	<keyword>Pathogen Inactivation</keyword>
	<keyword>Platelets Components Stored</keyword>
	<keyword>Therapeutic Efficacy</keyword>
</DOC>